Behcet’s disease is a vasculitis of unknown etiology, it is most prevalent in Mediterranean area, the
most serious problem is ocular involvement, and with the use of the immunosuppressive agents, ocular
prognosis had significantly improved.
The interferon 2 is a biological agent used for the treatment of viral hepatitis and renal cell
carcinoma. It is used now for the treatment of Behcet’s disease, the mode of action of INF in Behcet’s
disease is still unknown, it has many immuno -modulatory effects, such as enhancement of HLA class (I)
antigen expression on the lymphoid cells, T and NK cell cyto-toxicity, and it diverts the T cell response.
Forty patients had been studied through (2006 - 2008) in Merjan Teaching Hospital to compare
the use of interferon 2 versus other immunosuppressive agents to show the difference especially in
refractory eye problems and vascular involvement.
Six to nine million units of interferon per week were given subcutaneously to (20) patients whom
either newly diagnosed or already had Behcet’s disease and did not respond to other immunosuppressive
agents , those patients are compared with other (20) patients whom already treated by other drugs like
cyclosporine, azothioprine and other immunosuppressive agents .
The duration of the treatment with interferon was (3-6) months and ophthalmologist and
rheumatologist did follow up for one year.
The mean age of the patients was (14-55) year, the group one included (14) males and (6) females
while group two included (13) males and (7) females.
The group one showed dramatic response to interferon, especially among the newly diagnosed
patients while those patients treated with other drugs got better response with the use of interferon alone.
Only three patients not responded to interferon, one was newly diagnosed and the other two were
already diagnosed.
Thirteen patients showed complete remission or became stable during follow up period.
While in group two, (8) patients showed relapse after stopping therapy, (2) patients showed
deterioration of the visual acuity and eye problems even with therapy and (10) patients showed complete
remission in the follow up period
From this study, we found that interferon 2 is the newly emerged therapy of Behcet’s disease and
its complications that are not responding to ordinary therapy.
Interferon2 is useful in the treatment of Behcet’s disease in Iraq and should be used to prevent
serious problems of the disease like blindness and vascular obstruction. |